Daniel Sejer Pedersen

This inventor holds 12 USPTO granted patents and 10 published patent applications and 1 EPO patent. Top assignees: Santaris Pharma A/s, Roche Innovation Center Copenhagen A/s, Adelaide Research & Innovation Pty Ltd. Active years: 2006-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Sejer Pedersen. Retrieved from https://idiyas.com/inventor/daniel-sejer-pedersen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 50.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 7.1

ph-index = 8

Forward Citations = 598(Granted Patents)

Location History:

Copenhagen, DK (2006)
Cambridge, GB (2009 - 2011)
Cambridge, DK (2013)
Adelaide, AU (2015)
Valby, DK (2015 - 2018)

Company Filing History:

Roche Innovation Center Copenhagen A/s

patents

1 out of 41

Adelaide Research & Innovation Pty Ltd

patents

4. 1 out of 389

Beijing University of Technology

patents

where one patent can have more than one assignee

Years Active: 2006-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9994850 - Antisense design (2018-06-12),

2. 9951333 - Antisense design (2018-04-24),

3. 9890383 - Antisense design (2018-02-13),

4. 9708614 - Antisense design (2017-07-18),

5. 9428534 - Antisense design (2016-08-30),

6. 9108978 - Antimicrobial compounds (2015-08-18),

7. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),

8. 8492390 - Synthesis of locked nucleic acid derivatives (2013-07-23),

9. 8084458 - Synthesis of locked nucleic acid derivatives (2011-12-27),

10. 7687617 - Oligonucleotides with alternating segments of locked and non-locked nucleotides (2010-03-30),

11. 7569575 - Synthesis of locked nucleic acid derivatives (2009-08-04),

12. 7153954 - Method for preparation of LNA phosphoramidites (2006-12-26),

Title: **Innovative Contributions of Daniel Sejer Pedersen in Antisense Therapy**

Introduction

Daniel Sejer Pedersen, an accomplished inventor based in Valby, Denmark, has significantly contributed to the field of pharmaceuticals with his innovative work. Holding a total of 12 patents, his research focuses on the development of novel therapies utilizing Locked Nucleic Acids (LNA). Through his inventive spirit and dedication, he has made impactful strides in antisense therapy.

Latest Patents

Among his latest inventions, Daniel Sejer Pedersen has developed a novel class of pharmaceuticals that incorporates Locked Nucleic Acid (LNA) for antisense therapy. These innovative oligonucleotides exhibit enhanced antisense properties and are composed of at least one LNA variant, specifically beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. Notably, his designs can integrate DNA and/or RNA nucleotides, pushing the boundaries of therapeutic possibilities.

Career Highlights

Daniel has worked with prominent organizations in the pharmaceutical sector, including Santaris Pharma A/S and Roche Innovation Center Copenhagen A/S. His experiences at these leading companies have enriched his expertise and provided him with a platform to advance his groundbreaking research in the field of pharmaceuticals.

Collaborations

Throughout his career, Daniel Sejer Pedersen has collaborated with several esteemed colleagues, including Troels Koch and Signe M. Christensen. These partnerships have fostered a dynamic collaborative environment, facilitating innovative ideas and reinforcing the importance of teamwork in scientific advancements.

Conclusion

In summary, Daniel Sejer Pedersen stands out as a notable inventor dedicated to revolutionizing antisense therapy through his work with Locked Nucleic Acids. His impressive patent portfolio and collaborations highlight his contributions to modern pharmaceuticals and underscore the vital role of innovation in healthcare advancements.

Profile summary based on public USPTO records.